Related references
Note: Only part of the references are listed.Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
Qi Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Kai Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
Miguel A. Villalona-Calero et al.
CANCER (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
Xing Cheng et al.
JOURNAL OF VIROLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Youra Kim et al.
VIRUSES-BASEL (2015)
Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro
Nadia Luheshi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
Elizabeth Ilett et al.
MOLECULAR THERAPY (2014)
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells
Matthias Woelfl et al.
NATURE PROTOCOLS (2014)
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Jasper G. van den Boorn et al.
IMMUNITY (2013)
Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response
Giovanna Schiavoni et al.
FRONTIERS IN IMMUNOLOGY (2013)
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
Dmitriy Zamarin et al.
FUTURE MICROBIOLOGY (2012)
Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion
Soren Jensen et al.
JOURNAL OF VIROLOGY (2012)
CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Christine Zoglmeier et al.
CLINICAL CANCER RESEARCH (2011)
RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus Infection
Jan Rehwinkel et al.
CELL (2010)
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
Uciane K. Scarlett et al.
CANCER RESEARCH (2009)
Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase
Mostafa Jarahian et al.
JOURNAL OF VIROLOGY (2009)
Human-hemato-lymphoid-system mice: Opportunities and challenges
Markus G. Manz
IMMUNITY (2007)
An optimized clinical regimen for the oncolytic virus PV701
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2007)
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
AI Freeman et al.
MOLECULAR THERAPY (2006)
Share Paper
